Outsmarting Ovarian Cancer

Biochemist Sharon Stack hopes to advance the field of ovarian cancer by exploring the tumor and host-related factors that influence its metastatic process.

Black and white portrait by Mariella Bodemeier Loayza Careaga, PhD
| 4 min read
An artistic illustration of the female reproductive system.

Ovarian cancer is the second most frequent gynecologic cancer in the United States, and it kills more women than any other cancer of the female reproductive system.

©ISTOCK, Dusan Stankovic

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

As an undergraduate student at Clemson University, Sharon Stack became fascinated with the study of the chemical processes and molecular interactions that take place inside living cells. While Stack’s early biochemistry studies were not in the cancer field, losing a family member to the disease refocused her research interest and motivated her to dive into the world of oncology.

The photo shows a woman wearing a green blazer and smiling at the camera.
In her lab at the University of Notre Dame, biochemist Sharon Stack investigates tumor- and host-related factors that regulate ovarian cancer metastasis.
University of Notre Dame

Now, as a biochemist at the University of Notre Dame, Stack and her team collaborate with other scientists to investigate the processes and factors that contribute to ovarian cancer metastasis in the hope that their research might help fight this disease.

Stack was nominated for this interview through The Scientist’s Peer Profile Program submissions.

What motivated you to research ovarian cancer?

When I started studying ovarian cancer as a postdoctoral researcher in the early 1990s, it was an understudied disease. One in 87 women develops ovarian cancer during her lifetime, and the survival rate of those who have ovarian cancer with metastatic disease has not increased much over the past 30 to 40 years.1 The fact that ovarian cancer is such a pressing clinical problem motivates us to study it. As I learned more about it, I realized that ovarian cancer has a unique and interesting mechanism of metastasis, which stimulated me to keep investigating it.

What did you focus on when you first started studying ovarian cancer?

In the early days of my lab, we looked at ovarian cancer from a cell perspective. Tumors that shed from the ovary do not metastasize through the bloodstream like other cancer cells do. Instead, they adhere to tissues in the peritoneal cavity and seed multiple metastatic sites. To anchor themselves in these different tissues, the cells release proteases to degrade the extracellular matrix. Understanding the process of extracellular matrix proteolysis was one of our early goals, and we found that ovarian cancer cells produce potent matrix-degrading proteases.2

We were also interested in exploring the process by which tumor cells adhere to peritoneal tissues. We decided to look at cell-cell and cell-matrix adhesion molecules and how they interact in the context of ovarian cancer metastasis.3,4

How do aging and obesity influence ovarian cancer metastasis?

To investigate the interplay between aging, obesity, and tumor cells, we use mouse models. On the aging side, we found that older mice have a higher tumor burden as well as changes in peritoneal immunity compared to younger animals.5 Since the peritoneal cavity is rich in collagen, we reasoned that the increased tumor burden could be due to a collagen that is more susceptible to degradation by cancer cells. We found that tumor cells do not degrade more collagen in older mice. Instead, aged collagen has more fenestrations, which might provide enough space for tumor cells to proliferate and spread.6

To study the effects of obesity on ovarian cancer metastasis, we looked at tumor burden in mice that were fed a high-fat diet versus those on a standard diet. We found that animals fed the high-fat diet had more tumors in peritoneal organs and adipose tissue, showed changes in the proportion of some immune cells, and responded poorly to standard of care chemotherapy for ovarian cancer compared to mice on a standard diet.7,8

What questions would you like to see cancer researchers address in the coming years?

Our studies on aging and obesity showed that these factors alter the peritoneal immune landscape in mouse models of ovarian cancer. Since immunotherapy is a huge area in the cancer field, it would be interesting to figure out how to target this abnormal immunity to potentially improve the survival of ovarian cancer patients.

Another important area would be to understand cancer mutational processes in more diverse populations since most of what researchers know about cancer comes from data collected in people of European ancestry. Diversifying the population from which researchers obtain data and samples would allow them to explore the similarities and differences in tumor mutational pathways among these individuals, potentially revealing therapeutic targets that are appropriate for some patients and not others.

This interview has been edited for length and clarity.

Keywords

Meet the Author

  • Black and white portrait by Mariella Bodemeier Loayza Careaga, PhD

    Mariella Bodemeier Loayza Careaga, PhD

    Mariella is an assistant editor at The Scientist. She has a background in neuroscience, and her work has appeared in Drug Discovery News and Massive Science.
Share
You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio